{
    "organizations": [],
    "uuid": "9b8e03e1c1084d55af89ce4d7afa65295256d198",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/06/globe-newswire-aviragen-adjourns-special-meeting-of-stockholders-until-february-9-2018.html",
    "ord_in_thread": 0,
    "title": "Aviragen Adjourns Special Meeting of Stockholders Until February 9, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "ATLANTA, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced that its Special Meeting of Stockholders, scheduled for and convened on February 6, 2018, has been adjourned to provide the Company’s stockholders additional time to consider and vote FOR Aviragen’s proposed merger with Vaxart, Inc. Aviragen intends to reconvene the Special Meeting on February 9, 2018 at 12:00 pm EST.\nThe Aviragen Board of Directors unanimously recommends that stockholders vote FOR the proposals necessary to approve the proposed merger. Stockholders of record at the close of business on January 2, 2018 are entitled to and are being requested to vote. If a stockholder has already submitted their proxy card and does not wish to change their vote, no further action is required at this time.\nAviragen encourages stockholders that have not yet voted their shares to vote by 11:59 pm EST on February 8, 2018. Each vote is extremely important, no matter how many or how few shares are owned. The affirmative vote of the holders of a majority of the shares of Aviragen common stock properly cast at the Aviragen Special Meeting, presuming a quorum is present, is required to approve the proposed merger. Please take a moment to vote FOR the proposals necessary to approve the proposed merger today – by telephone, by Internet or by signing, dating and returning the WHITE proxy card. Please discard any BLUE proxy card you may receive from the CAS Group.\nStockholders with questions or requiring assistance voting their shares should contact Aviragen’s proxy solicitor, D.F. King & Co., Inc., toll-free at (800) 967-5074. Each vote is extremely important, no matter how many or how few shares are owned.\nAbout Aviragen Therapeutics\nAviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. It has three Phase 2 clinical stage compounds: BTA074 (teslexivir), an antiviral treatment for condyloma caused by human papillomavirus types 6 and 11; vapendavir, a capsid inhibitor for the prevention or treatment of rhinovirus (RV) upper respiratory infections; and BTA585 (enzaplatovir), a fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections. Aviragen also receives royalties from marketed influenza products, Relenza® and Inavir®. For additional information, please visit www.aviragentherapeutics.com .\nAviragen Therapeutics® is a registered trademark. Relenza® is a registered trademark of GlaxoSmithKline Pharmaceuticals, Ltd., and Inavir® is a registered trademark of Daiichi Sankyo Company, Ltd.\nForward Looking Statements\nThis press release contains forward-looking statements about Aviragen Therapeutics, Inc. and Vaxart Inc., and their respective businesses, business prospects, strategy and plans, including but not limited to statements regarding anticipated preclinical and clinical drug development activities, timelines and market opportunities; the combined company being well-funded to advance its programs; the potential of Vaxart’s flu vaccine to produce better efficacy and in a timely manner; and the combined company’s ability to accelerate development of Vaxart’s vaccine candidates and generate near and long term value for stockholders. All statements other than statements of historical facts included in this press release are forward looking statements. The words “anticipates,” “may,” “can,” “plans,” “believes,” “estimates,” “expects,” “projects,” “intends,” “likely,” “will,” “should,” “to be,” and any similar expressions or other words of similar meaning are intended to identify those assertions as forward looking statements. These forward looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation: the risk that the conditions to the closing of the merger are not satisfied, the failure to timely or at all obtain stockholder approval for the merger; uncertainties as to the timing of the consummation of the merger and the ability of each of Aviragen and Vaxart to consummate the merger; risks related to Aviragen’s ability to correctly estimate its operating expenses and its expenses associated with the merger; risks related to the market price of Aviragen’s common stock relative to the exchange ratio; the ability of Aviragen or Vaxart to protect their respective intellectual property rights; competitive responses to the merger; unexpected costs, charges or expenses resulting from the merger; and potential adverse reactions or changes to business relationships resulting from the announcement or completion of the merger. The vaccine candidates that Vaxart develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, future clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release and such vaccine candidates may not successfully commercialized. Additional factors that may cause actual results to differ materially from such forward looking statements include those identified under the caption “Risk Factors” in the documents filed by Aviragen with the Securities and Exchange Commission from time to time, including its Proxy/Prospectus on Form S-4, Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except to the extent required by applicable law or regulation, neither Aviragen nor Vaxart undertakes any obligation to update the forward-looking statements included in this press release to reflect subsequent events or circumstances.\nAdditional Information About the Merger and Where to Find It\nIn connection with the proposed strategic merger, Aviragen and Vaxart have filed relevant materials with the Securities and Exchange Commission, or the SEC, including a registration statement on Form S-4, as amended, that contains a prospectus and a joint proxy statement. Investors may obtain the proxy statement/prospectus, as well as other filings containing important information about Aviragen, Vaxart and the merger, free of charge at the SEC’s web site ( www.sec.gov ). In addition, investors and security holders may obtain free copies of the documents filed with the SEC by Aviragen by directing a written request to: Aviragen Therapeutics, Inc. 2500 Northwinds Parkway, Suite 100, Alpharetta, GA 30009, Attention: Corporate Secretary or delivered via email to investors@aviragentherapeutics.com . Investors and security holders are urged to read the proxy statement/prospectus and the other relevant materials before making any voting or investment decision with respect to the merger.\nThis communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.\nParticipants in the Solicitation\nAviragen and Vaxart and their respective directors and officers and certain of their other members of management and employees may be deemed to be participants in the solicitation of proxies from the stockholders of Aviragen in connection with the proposed transaction. Information regarding the special interests of these directors and executive officers in the merger are included in the proxy statement/prospectus referred to above. Additional information regarding the directors and executive officers of Aviragen is also included in Aviragen’s Annual Report on Forms 10-K for the year ended June 30, 2017, filed with the SEC on September 1, 2017, and the Form 10-K/A filed with the SEC on October 20, 2017. These documents are available free of charge from the sources indicated above.\nContacts\nMark Colonnese\nExecutive Vice President and Chief Financial Officer\nAviragen Therapeutics, Inc.\n(678) 221-3381\nmcolonnese@aviragentherapeutics.com\nBeth DelGiacco\nStern Investor Relations, Inc.\n(212) 362-1200\nbeth@sternir.com\nKristian Klein\nD.F. King & Co., Inc.\n(212) 232-2247\nWinnie Lerner / Nick Leasure\nFinsbury\n(646) 805-2855\nSource:Aviragen Therapeutics, Inc.",
    "published": "2018-02-06T18:25:00.000+02:00",
    "crawled": "2018-02-06T18:48:59.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "atlanta",
        "globe",
        "newswire",
        "aviragen",
        "therapeutic",
        "nasdaq",
        "avir",
        "today",
        "announced",
        "special",
        "meeting",
        "stockholder",
        "scheduled",
        "convened",
        "february",
        "adjourned",
        "provide",
        "company",
        "stockholder",
        "additional",
        "time",
        "consider",
        "vote",
        "aviragen",
        "proposed",
        "merger",
        "vaxart",
        "aviragen",
        "intends",
        "reconvene",
        "special",
        "meeting",
        "february",
        "pm",
        "est",
        "aviragen",
        "board",
        "director",
        "unanimously",
        "recommends",
        "stockholder",
        "vote",
        "proposal",
        "necessary",
        "approve",
        "proposed",
        "merger",
        "stockholder",
        "record",
        "close",
        "business",
        "january",
        "entitled",
        "requested",
        "vote",
        "stockholder",
        "already",
        "submitted",
        "proxy",
        "card",
        "wish",
        "change",
        "vote",
        "action",
        "required",
        "time",
        "aviragen",
        "encourages",
        "stockholder",
        "yet",
        "voted",
        "share",
        "vote",
        "pm",
        "est",
        "february",
        "vote",
        "extremely",
        "important",
        "matter",
        "many",
        "share",
        "owned",
        "affirmative",
        "vote",
        "holder",
        "majority",
        "share",
        "aviragen",
        "common",
        "stock",
        "properly",
        "cast",
        "aviragen",
        "special",
        "meeting",
        "presuming",
        "quorum",
        "present",
        "required",
        "approve",
        "proposed",
        "merger",
        "please",
        "take",
        "moment",
        "vote",
        "proposal",
        "necessary",
        "approve",
        "proposed",
        "merger",
        "today",
        "telephone",
        "internet",
        "signing",
        "dating",
        "returning",
        "white",
        "proxy",
        "card",
        "please",
        "discard",
        "blue",
        "proxy",
        "card",
        "may",
        "receive",
        "ca",
        "group",
        "stockholder",
        "question",
        "requiring",
        "assistance",
        "voting",
        "share",
        "contact",
        "aviragen",
        "proxy",
        "solicitor",
        "king",
        "vote",
        "extremely",
        "important",
        "matter",
        "many",
        "share",
        "owned",
        "aviragen",
        "therapeutic",
        "aviragen",
        "therapeutic",
        "focused",
        "discovery",
        "development",
        "next",
        "generation",
        "antiviral",
        "treat",
        "infection",
        "limited",
        "therapeutic",
        "option",
        "affect",
        "significant",
        "number",
        "patient",
        "globally",
        "three",
        "phase",
        "clinical",
        "stage",
        "compound",
        "bta074",
        "teslexivir",
        "antiviral",
        "treatment",
        "condyloma",
        "caused",
        "human",
        "papillomavirus",
        "type",
        "vapendavir",
        "capsid",
        "inhibitor",
        "prevention",
        "treatment",
        "rhinovirus",
        "rv",
        "upper",
        "respiratory",
        "infection",
        "bta585",
        "enzaplatovir",
        "fusion",
        "protein",
        "inhibitor",
        "development",
        "treatment",
        "respiratory",
        "syncytial",
        "virus",
        "infection",
        "aviragen",
        "also",
        "receives",
        "royalty",
        "marketed",
        "influenza",
        "product",
        "additional",
        "information",
        "please",
        "visit",
        "aviragen",
        "registered",
        "trademark",
        "registered",
        "trademark",
        "glaxosmithkline",
        "pharmaceutical",
        "registered",
        "trademark",
        "daiichi",
        "sankyo",
        "company",
        "forward",
        "looking",
        "statement",
        "press",
        "release",
        "contains",
        "statement",
        "aviragen",
        "therapeutic",
        "vaxart",
        "respective",
        "business",
        "business",
        "prospect",
        "strategy",
        "plan",
        "including",
        "limited",
        "statement",
        "regarding",
        "anticipated",
        "preclinical",
        "clinical",
        "drug",
        "development",
        "activity",
        "timeline",
        "market",
        "opportunity",
        "combined",
        "company",
        "advance",
        "program",
        "potential",
        "vaxart",
        "flu",
        "vaccine",
        "produce",
        "better",
        "efficacy",
        "timely",
        "manner",
        "combined",
        "company",
        "ability",
        "accelerate",
        "development",
        "vaxart",
        "vaccine",
        "candidate",
        "generate",
        "near",
        "long",
        "term",
        "value",
        "stockholder",
        "statement",
        "statement",
        "historical",
        "fact",
        "included",
        "press",
        "release",
        "forward",
        "looking",
        "statement",
        "word",
        "anticipates",
        "may",
        "plan",
        "belief",
        "estimate",
        "expects",
        "project",
        "intends",
        "likely",
        "similar",
        "expression",
        "word",
        "similar",
        "meaning",
        "intended",
        "identify",
        "assertion",
        "forward",
        "looking",
        "statement",
        "forward",
        "looking",
        "statement",
        "involve",
        "substantial",
        "risk",
        "uncertainty",
        "could",
        "cause",
        "actual",
        "result",
        "differ",
        "materially",
        "anticipated",
        "including",
        "without",
        "limitation",
        "risk",
        "condition",
        "closing",
        "merger",
        "satisfied",
        "failure",
        "timely",
        "obtain",
        "stockholder",
        "approval",
        "merger",
        "uncertainty",
        "timing",
        "consummation",
        "merger",
        "ability",
        "aviragen",
        "vaxart",
        "consummate",
        "merger",
        "risk",
        "related",
        "aviragen",
        "ability",
        "correctly",
        "estimate",
        "operating",
        "expense",
        "expense",
        "associated",
        "merger",
        "risk",
        "related",
        "market",
        "price",
        "aviragen",
        "common",
        "stock",
        "relative",
        "exchange",
        "ratio",
        "ability",
        "aviragen",
        "vaxart",
        "protect",
        "respective",
        "intellectual",
        "property",
        "right",
        "competitive",
        "response",
        "merger",
        "unexpected",
        "cost",
        "charge",
        "expense",
        "resulting",
        "merger",
        "potential",
        "adverse",
        "reaction",
        "change",
        "business",
        "relationship",
        "resulting",
        "announcement",
        "completion",
        "merger",
        "vaccine",
        "candidate",
        "vaxart",
        "develops",
        "may",
        "progress",
        "clinical",
        "development",
        "receive",
        "required",
        "regulatory",
        "approval",
        "within",
        "expected",
        "timeline",
        "addition",
        "future",
        "clinical",
        "trial",
        "may",
        "confirm",
        "safety",
        "potency",
        "product",
        "characteristic",
        "described",
        "assumed",
        "press",
        "release",
        "vaccine",
        "candidate",
        "may",
        "successfully",
        "commercialized",
        "additional",
        "factor",
        "may",
        "cause",
        "actual",
        "result",
        "differ",
        "materially",
        "forward",
        "looking",
        "statement",
        "include",
        "identified",
        "caption",
        "risk",
        "factor",
        "document",
        "filed",
        "aviragen",
        "security",
        "exchange",
        "commission",
        "time",
        "time",
        "including",
        "form",
        "annual",
        "report",
        "form",
        "quarterly",
        "report",
        "form",
        "current",
        "report",
        "form",
        "cautioned",
        "place",
        "undue",
        "reliance",
        "statement",
        "speak",
        "date",
        "press",
        "release",
        "except",
        "extent",
        "required",
        "applicable",
        "law",
        "regulation",
        "neither",
        "aviragen",
        "vaxart",
        "undertakes",
        "obligation",
        "update",
        "statement",
        "included",
        "press",
        "release",
        "reflect",
        "subsequent",
        "event",
        "circumstance",
        "additional",
        "information",
        "merger",
        "find",
        "connection",
        "proposed",
        "strategic",
        "merger",
        "aviragen",
        "vaxart",
        "filed",
        "relevant",
        "material",
        "security",
        "exchange",
        "commission",
        "sec",
        "including",
        "registration",
        "statement",
        "form",
        "amended",
        "contains",
        "prospectus",
        "joint",
        "proxy",
        "statement",
        "investor",
        "may",
        "obtain",
        "proxy",
        "well",
        "filing",
        "containing",
        "important",
        "information",
        "aviragen",
        "vaxart",
        "merger",
        "free",
        "charge",
        "sec",
        "web",
        "site",
        "addition",
        "investor",
        "security",
        "holder",
        "may",
        "obtain",
        "free",
        "copy",
        "document",
        "filed",
        "sec",
        "aviragen",
        "directing",
        "written",
        "request",
        "aviragen",
        "therapeutic",
        "northwinds",
        "parkway",
        "suite",
        "alpharetta",
        "ga",
        "attention",
        "corporate",
        "secretary",
        "delivered",
        "via",
        "email",
        "investor",
        "investor",
        "security",
        "holder",
        "urged",
        "read",
        "proxy",
        "relevant",
        "material",
        "making",
        "voting",
        "investment",
        "decision",
        "respect",
        "merger",
        "communication",
        "shall",
        "constitute",
        "offer",
        "sell",
        "solicitation",
        "offer",
        "sell",
        "solicitation",
        "offer",
        "buy",
        "security",
        "shall",
        "sale",
        "security",
        "jurisdiction",
        "offer",
        "solicitation",
        "sale",
        "would",
        "unlawful",
        "prior",
        "registration",
        "qualification",
        "security",
        "law",
        "jurisdiction",
        "offering",
        "security",
        "shall",
        "made",
        "except",
        "mean",
        "prospectus",
        "meeting",
        "requirement",
        "section",
        "security",
        "act",
        "amended",
        "participant",
        "solicitation",
        "aviragen",
        "vaxart",
        "respective",
        "director",
        "officer",
        "certain",
        "member",
        "management",
        "employee",
        "may",
        "deemed",
        "participant",
        "solicitation",
        "proxy",
        "stockholder",
        "aviragen",
        "connection",
        "proposed",
        "transaction",
        "information",
        "regarding",
        "special",
        "interest",
        "director",
        "executive",
        "officer",
        "merger",
        "included",
        "proxy",
        "referred",
        "additional",
        "information",
        "regarding",
        "director",
        "executive",
        "officer",
        "aviragen",
        "also",
        "included",
        "aviragen",
        "annual",
        "report",
        "form",
        "year",
        "ended",
        "june",
        "filed",
        "sec",
        "september",
        "form",
        "filed",
        "sec",
        "october",
        "document",
        "available",
        "free",
        "charge",
        "source",
        "indicated",
        "contact",
        "mark",
        "colonnese",
        "executive",
        "vice",
        "president",
        "chief",
        "financial",
        "officer",
        "aviragen",
        "therapeutic",
        "mcolonnese",
        "beth",
        "delgiacco",
        "stern",
        "investor",
        "relation",
        "beth",
        "kristian",
        "klein",
        "king",
        "winnie",
        "lerner",
        "nick",
        "leasure",
        "finsbury",
        "source",
        "aviragen",
        "therapeutic",
        "inc"
    ]
}